Novo Nordisk A/S Chief Executive Officer Mike Doustdar discusses the possible launch of a new obesity drug called CagriSema. "We are hopeful that we will be able to get the timely approval from the FDA at the end of this year and launch it at the beginning of next year," Doustdar says. He speaks on Bloomberg Television after the company boosted its forecast for the year once again, sparking optimism after the new Wegovy pill and the older shot Ozempic helped buoy earnings. (Source: Bloomberg)
我们公开展示核心要点。创建免费账户后可继续阅读全文、保存、讨论，并结合市场和 OSINT 背景分析。